Shield Therapeutics
plc
("Shield"
or the "Company" or the "Group")
Grant of Share
Options
London, UK, 13 February 2025: Shield Therapeutics plc (LSE: STX), a commercial stage
pharmaceutical company specialising in iron deficiency,
announces that on 12 February
2025 it granted share awards in the form of options over ordinary
shares in the capital of the Company ("Ordinary Shares") under
Shield Therapeutics' Retention and Performance Share Plan ("RPSP")
to the Group's Chief Executive Officer ("CEO") as part of his
onboarding.
The following options have been
granted to Anders Lundstrom, CEO, who is deemed a PDMR:
|
Name
|
Option Plan
|
Number of Ordinary Shares
under Option
|
Vesting
Date
|
|
Anders
Lundstrom
|
RPSP
|
5,000,000
|
Three years from date of grant,
subject to Mr Lundstrom remaining in office as at the date of
vesting.
|
The proportion of total options
awarded to Anders Lundstrom is approximately 0.5% of the total
number of AIM securities in issue at this time.
Anders Lundstrom currently holds
10,000 ordinary shares in the Company.
|
1.
|
Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them
("PCA")
|
|
a)
|
Name
|
Anders Lundstrom
|
|
2.
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification/
amendment
|
Initial Notification
|
|
3.
|
Details of the Issuer
|
|
a)
|
Name
|
Shield Therapeutics plc
|
|
b)
|
LEI code
|
213800G74QWY15FC3W71
|
|
4.
|
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the financial
instrument
Identification code
|
Options over new Ordinary
Shares
ISIN: GB00BYV81293
|
|
b)
|
Nature of the transaction
|
Grant of awards over new Ordinary
Shares under the Company's Retention and Performance Share
Plan.
|
|
c)
|
Price(s) and volumes(s)
|
2025 RPSP Award
|
Price (£)
|
Volume
|
|
0.037
|
5,000,000
|
|
|
d)
|
Aggregated information
- Aggregate
volume
- Price
|
Awards granted over 5,000,000 shares
in total
3.7p exercise price
|
|
e)
|
Date of the transaction
|
12 February 2025
|
|
f)
|
Place of the transaction
|
Outside of trading venue
|
For
further information please contact:
|
Shield Therapeutics plc
|
www.shieldtherapeutics.com
|
|
Anders Lundstrom, CEO
|
+44 (0)
191 511 8500
|
|
Santosh Shanbhag, CFO
Stephanie Hicks, Investor
Relations
|
Investorrelations@shieldtx.com
|
|
|
|
|
Nominated Adviser and Joint Broker
|
|
|
Peel Hunt LLP
|
|
|
James Steel / Patrick
Birkholm
|
+44 (0)20
7418 8900
|
|
|
|
|
Joint Broker
|
+44 (0)20
7220 0500
|
|
Cavendish Ltd
|
|
|
Geoff Nash / Rory Sale / Nigel Birks
/ Harriet
Ward
|
|
|
|
|
|
Financial PR & IR Advisor
|
|
|
Walbrook PR
|
|
|
Alice Woodings / Lianne
Applegarth
|
+44 (0)20
7933 8780 or shield@walbrookpr.com
|
About Iron Deficiency and
ACCRUFeR®/FeRACCRU®
Clinically low iron levels (aka iron
deficiency, ID) can cause serious health problems for adults of all
ages, across multiple therapeutic areas. Together, ID and ID with
anemia (IDA) affect about 20 million people in the US and represent
a $2.3B market opportunity. As the first and only FDA approved oral
iron to treat ID/IDA, ACCRUFeR® has the potential to meet an
important unmet medical need for both physicians and
patients.
ACCRUFeR®/FeRACCRU® (ferric maltol)
is a novel, stable, non-salt-based oral therapy for adults with
ID/IDA. The drug has a novel mechanism of absorption compared to other oral
iron therapies and has been shown to be an efficacious and
well-tolerated therapy in a range of clinical trials. More
information about ACCRUFeR®/FeRACCRU®, including the product
label, can be found at: www.accrufer.com and www.feraccru.com.
About Shield Therapeutics plc
Shield is a commercial stage
specialty pharmaceutical company that delivers ACCRUFeR®/FeRACCRU®
(ferric maltol), an innovative and differentiated pharmaceutical
product, to address a significant unmet need for patients suffering
from iron deficiency, with or without anemia. The Company has launched ACCRUFeR® in the U.S. with an
exclusive, multi-year collaboration agreement with Viatris Inc.
Outside of the U.S., the Company has licensed the rights to four
specialty pharmaceutical companies. FeRACCRU® is commercialized in
the UK and European Union by Norgine B.V., which also has marketing
rights in Australia and New Zealand. Shield also has an exclusive
license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd.,
for the development and commercialization of ACCRUFeR®/ FeRACCRU®
in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd.
for the Republic of Korea, and with KYE Pharmaceuticals Inc. for
Canada.
ACCRUFeR®/FeRACCRU® has patent
coverage until the mid-2030s.
ACCRUFeR®/FeRACCRU® are registered
trademarks of Shield Therapeutics.
